Pharmaceutical Company Submits FDA Application For Tourette Syndrome Clinical Trial
$SPRC - SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome.
Disclaimer: This article is intended for informational and educational purposes only. It does not constitute medical advice or professional recommendations. Readers are urged to consult with healthcare professionals for specific medical concerns.
We are working endlessly to provide free insights on the stock market every day, and …